Novo Nordisk's China President Zhou to step down in March

Novo Nordisk's China President, Christine Zhou, will step down at the end of March. She has led the company's operations in China, Taiwan, Hong Kong, and Macau since 2018, overseeing the launch of key products like Ozempic and Wegovy. Her departure comes as Novo faces increasing competition from Eli Lilly and local firms, including Sciwind Biosciences, which recently received approval for its diabetes treatment. Additionally, a local patent for the active ingredients in Wegovy and Ozempic is set to expire this year, posing further challenges for Novo in the Chinese market.